Mitigating alemtuzumab-associated autoimmunity in MS
نویسندگان
چکیده
منابع مشابه
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Treatment of early relapsing-remitting multiple sclerosis with the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath [registered trade mark]) significantly reduced the risk of relapse and accumulation of disability compared with interferon β-1a in a phase 2 trial [Coles et al., (Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786-801)]...
متن کاملPredicting autoimmunity after alemtuzumab treatment of multiple sclerosis.
OBJECTIVE We have previously shown that autoimmunity following alemtuzumab treatment of multiple sclerosis can be predicted by high baseline serum interleukin IL-21 (IL-21), as measured using a now 'redundant' enzyme linked immunosorbent assay (ELISA). Here we ask whether currently available ELISAs have similar prognostic value. DESIGN Serum IL-21 from 141 individuals with relapsing remitting...
متن کاملAlemtuzumab improves preexisting disability in active relapsing-remitting MS patients
OBJECTIVE To characterize effects of alemtuzumab treatment on measures of disability improvement in patients with relapsing-remitting multiple sclerosis (RRMS) with inadequate response (≥1 relapse) to prior therapy. METHODS Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II, a 2-year randomized, rater-blinded, active-controlled, head-to-head, phase 3 trial, compar...
متن کاملAlemtuzumab CARE-MS II 5-year follow-up
OBJECTIVE To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. METHODS In the 2-year Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II study (NCT00548405), alemtuzumab-treated patients received 2 courses (baseline and 12 months later). Patients could enter an...
متن کاملBRAIN A JOURNAL OF NEUROLOGY Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity
Treatment of early relapsing–remitting multiple sclerosis with the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath [registered trade mark]) significantly reduced the risk of relapse and accumulation of disability compared with interferon b-1a in a phase 2 trial [Coles et al., (Alemtuzumab vs. interferon b-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786–801)]...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology - Neuroimmunology Neuroinflammation
سال: 2020
ISSN: 2332-7812
DOI: 10.1212/nxi.0000000000000868